17. Assessment of interaction, overall survival in all cancer patients.

Overall survival, all cancer patients	Patients included	P value for interaction
Total	13933
Patient level characteristics
Hb at baseline (continuous)	13407	0.7547
Hb at baseline (categorical 1)	13407	0.6326
Hb at baseline (categorical 2)	13407	0.8292
Tumor (categorical 1)	13891	0.2315
Tumor (categorical 2)	13891	0.2122
Sex plus	13933	0.1480
Age (continuous)	13921	0.3758
Age (categorical)	13921	0.2610
Hct (continuous)	11036	0.8998
Hct (categorical)	11036	0.0330
Baseline serum EPO (continuous)	5651	0.1424
Baseline serum EPO (categorical)	5651	0.8116
ECOG	10112	0.4115
ECOG (0,1,2 vs 3,4)	10225	0.4980
BMI (categorical)	11445	0.7189
History of thromboembolic events	9620	0.8964
History of cardiovascular events	10322	0.6886
History of hypertension	9620	0.5700
History of diabetes mellitus	8025	0.9435
Geographical region [region_cat]	13532	0.9000
Metastatic vs non‐metastatic	12152	0.8573
Planned Hb ceiling (categorical 1)	13730	0.3973
Planned Hb ceiling (categorical 2)	13730	0.5976
Study level characteristics
Placebo controlled	13933	0.2932
Randomization (adequate vs unclear)	13933	0.8042
Allocation (adequate vs unclear)	13933	0.4945
Endpoint overall survival	13933	0.3866
Designed for long term follow up (binary)	13933	0.6423
Year of last patient randomized into study (categorical)	13933	0.1285
Source of data (company versus independent)	13933	0.5736
Patient population (chemotherapy, radio‐chemo‐ therapy, none, mixed)	13933	0.1133
Iron category	13933	0.4786
Planned ESA treatment duration (categorical)	13933	0.7393
Planned weekly ESA dosage (categorical)	13933	0.8780
Planned frequency of ESA administration (categorical)	13933	0.0748

*P value for interaction based on LR test, patients with missing data are excluded from LR test